{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:55:58Z","timestamp":1793451358457,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170309"],"award-info":[{"award-number":["82170309"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mAFA-II cluster randomised trial demonstrated the efficacy of a mobile health-technology implemented \u2018Atrial fibrillation Better Care\u2019 (ABC) pathway (mAFA intervention) for integrated care management of patients with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of mAFA intervention across phenotypes of patients with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a latent-class analysis (LCA) according to eight variables, including age and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The mAFA-II trial enrolled AF patients between June 2018 and August 2019 across 40 centres in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>We evaluated the interaction between the groups identified through LCA, and the effect of mAFA intervention on the risk of the primary composite outcome of all-cause death, stroke\/thromboembolism, and rehospitalisations. Results were expressed as adjusted hazard ratio (aHR) and 95% confidence intervals (95% CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      Across the 3324 patients included in the trial (mean age 68.5\u2009\u00b1\u200913.9\u00a0years, 38.0% females), we identified three phenotypes: (i) low morbidity phenotype (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091234, 37.1%), (ii) hypertensive\/coronary artery disease (CAD) phenotype (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091534, 46.2%), and (iii) mixed morbidity phenotype (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009556, 16.7%). The effect of mAFA intervention on the primary outcome appeared greater in the low morbidity phenotype (aHR, 0.08; 95% CI 0.02\u20130.33) compared to the hypertensive\/CAD (aHR, 0.30; 95% CI 0.16\u20130.58) and the mixed morbidity phenotype (aHR, 0.68; 95% CI 0.37\u20131.24), with a statistically significant interaction (\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>int<\/jats:sub>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with AF, the ABC pathway improved prognosis across different comorbidity phenotypes, although with some differences in the magnitude of risk reduction. Patients with more complex phenotypes require further efforts to improve their outcomes, considering their high baseline risk of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>WHO International Clinical Trials Registry Platform (ICTRP) Registration number: ChiCTR-OOC-17014138.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-024-09037-6","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T12:02:59Z","timestamp":1730116979000},"page":"1238-1247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of the ABC Pathway for Integrated Care Across Phenotypes of Patients with Atrial Fibrillation: A Latent-Class Analysis Report from the mAFA-II Clinical Trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-4435","authenticated-orcid":false,"given":"Bernadette","family":"Corica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Francesco","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Antonio","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the mAF-App II trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"9037_CR1","unstructured":"World Health Organization. The World Health Organization Report 2002: reducing risks, promoting healthy life. WHO Library Cataloguing-in Publication Data. Published online 2002:232."},{"issue":"2","key":"9037_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cger.2016.01.001","volume":"32","author":"MA Chen","year":"2016","unstructured":"Chen MA. Multimorbidity in Older Adults with Atrial Fibrillation. Clin Geriatr Med. 2016;32(2):315-329. https:\/\/doi.org\/10.1016\/j.cger.2016.01.001.","journal-title":"Clin Geriatr Med."},{"issue":"12","key":"9037_CR3","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","volume":"94","author":"M Proietti","year":"2019","unstructured":"Proietti M, Marzona I, Vannini T, et al. Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clin Proc. 2019;94(12):2427-2436. https:\/\/doi.org\/10.1016\/j.mayocp.2019.06.012.","journal-title":"Mayo Clin Proc."},{"key":"9037_CR4","doi-asserted-by":"publisher","first-page":"100386","DOI":"10.1016\/j.lanepe.2022.100386","volume":"17","author":"J Wu","year":"2022","unstructured":"Wu J, Nadarajah R, Nakao YM, et al. Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3\u00b74 million individuals. The Lancet Regional Health - Europe. 2022;17:100386. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100386.","journal-title":"The Lancet Regional Health - Europe."},{"key":"9037_CR5","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/J.IJCHA.2021.100885","volume":"37","author":"E Watanabe","year":"2021","unstructured":"Watanabe E, Inoue H, Atarashi H, et al. Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry. Int J Cardiol Heart Vasc. 2021;37:100885. https:\/\/doi.org\/10.1016\/J.IJCHA.2021.100885.","journal-title":"Int J Cardiol Heart Vasc."},{"key":"9037_CR6","doi-asserted-by":"publisher","unstructured":"Vitolo M, Proietti M, Shantsila A, Boriani G, Lip GYH. Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. Biomedicines. 2021;9(7). https:\/\/doi.org\/10.3390\/BIOMEDICINES9070843.","DOI":"10.3390\/BIOMEDICINES9070843"},{"key":"9037_CR7","doi-asserted-by":"publisher","unstructured":"Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis. Thromb Haemost. Published online 2023. https:\/\/doi.org\/10.1055\/S-0043-1770724.","DOI":"10.1055\/S-0043-1770724"},{"key":"9037_CR8","doi-asserted-by":"publisher","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Thromb Haemost. Published online June 27, 2023. https:\/\/doi.org\/10.1055\/S-0043-1769735.","DOI":"10.1055\/S-0043-1769735"},{"issue":"12","key":"9037_CR9","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1055\/s-0042-1756355","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Bonini N, et al. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022;122(12):2030-2041. https:\/\/doi.org\/10.1055\/s-0042-1756355.","journal-title":"Thromb Haemost."},{"issue":"5","key":"9037_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/CHEST.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey. Chest. 2010;138(5):1093-1100. https:\/\/doi.org\/10.1378\/CHEST.10-0134.","journal-title":"Chest."},{"issue":"12","key":"9037_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1055\/S-0038-1675400","volume":"118","author":"ED Borre","year":"2018","unstructured":"Borre ED, Goode A, Raitz G, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018;118(12):2171-2187. https:\/\/doi.org\/10.1055\/S-0038-1675400.","journal-title":"Thromb Haemost."},{"issue":"11","key":"9037_CR12","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/EUROPACE\/EUAC020","volume":"24","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao TF, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace. 2022;24(11):1844-1871. https:\/\/doi.org\/10.1093\/EUROPACE\/EUAC020.","journal-title":"Europace."},{"issue":"1","key":"9037_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","volume":"20","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Vitolo M, et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 2022;20(1):326. https:\/\/doi.org\/10.1186\/s12916-022-02526-7.","journal-title":"BMC Med."},{"issue":"1","key":"9037_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/JAMACARDIO.2017.4665","volume":"3","author":"T Inohara","year":"2018","unstructured":"Inohara T, Shrader P, Pieper K, et al. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiol. 2018;3(1):54-63. https:\/\/doi.org\/10.1001\/JAMACARDIO.2017.4665.","journal-title":"JAMA Cardiol."},{"issue":"7","key":"9037_CR15","doi-asserted-by":"publisher","first-page":"24319","DOI":"10.1161\/JAHA.121.024319","volume":"11","author":"A Kotalczyk","year":"2022","unstructured":"Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH. Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry. J Am Heart Assoc. 2022;11(7):24319. https:\/\/doi.org\/10.1161\/JAHA.121.024319.","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"9037_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/NRCARDIO.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: An integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627-628. https:\/\/doi.org\/10.1038\/NRCARDIO.2017.153.","journal-title":"Nat Rev Cardiol."},{"issue":"13","key":"9037_CR17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/J.JACC.2020.01.052","volume":"75","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lane DA, Wang L, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75(13):1523-1534. https:\/\/doi.org\/10.1016\/J.JACC.2020.01.052.","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"9037_CR18","doi-asserted-by":"publisher","first-page":"2140071","DOI":"10.1001\/jamanetworkopen.2021.40071","volume":"4","author":"Y Yao","year":"2021","unstructured":"Yao Y, Guo Y, Lip GYH. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events among Patients with Multimorbidity: The mAFA-II Randomized Clinical Trial. JAMA Netw Open. 2021;4(12):2140071. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.40071.","journal-title":"JAMA Netw Open."},{"key":"9037_CR19","doi-asserted-by":"publisher","unstructured":"Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry. Thromb Haemost. 2024;124(1). https:\/\/doi.org\/10.1055\/S-0043-1772773.","DOI":"10.1055\/S-0043-1772773"},{"issue":"11","key":"9037_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1055\/S-0043-1769612","volume":"123","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial. Thromb Haemost. 2023;123(11):1042-1048. https:\/\/doi.org\/10.1055\/S-0043-1769612.","journal-title":"Thromb Haemost."},{"issue":"3","key":"9037_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/A-1515-9630","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the \u201cAtrial Fibrillation Better Care\u201d Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb Haemost. 2022;122(3):406-414. https:\/\/doi.org\/10.1055\/A-1515-9630.","journal-title":"Thromb Haemost."},{"issue":"1","key":"9037_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/S-0041-1739411","volume":"122","author":"TF Chao","year":"2022","unstructured":"Chao TF, Joung B, Takahashi Y, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2022;122(1):20-47. https:\/\/doi.org\/10.1055\/S-0041-1739411.","journal-title":"Thromb Haemost."},{"key":"9037_CR23","doi-asserted-by":"publisher","unstructured":"Guo Y, Lane DA, Wang L, et al. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF\u2010App) II randomised trial. Int J Clin Pract. 2019;73(7). https:\/\/doi.org\/10.1111\/ijcp.13352.","DOI":"10.1111\/ijcp.13352"},{"issue":"1","key":"9037_CR24","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/CCM.0000000000004710","volume":"49","author":"P Sinha","year":"2021","unstructured":"Sinha P, Calfee CS, Delucchi KL. Practitioner\u2019s Guide to Latent Class Analysis: Methodological Considerations and Common Pitfalls. Crit Care Med. 2021;49(1):e63. https:\/\/doi.org\/10.1097\/CCM.0000000000004710.","journal-title":"Crit Care Med."},{"key":"9037_CR25","doi-asserted-by":"publisher","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study. 2007;14(4):535-569. https:\/\/doi.org\/10.1080\/10705510701575396.","DOI":"10.1080\/10705510701575396"},{"key":"9037_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0095798420930932","volume":"4","author":"BE Weller","year":"2020","unstructured":"Weller BE, Bowen NK, Faubert SJ. Latent Class Analysis: A Guide to Best Practice. J Black Psychol. 2020(4):287-311. https:\/\/doi.org\/10.1177\/0095798420930932.","journal-title":"J Black Psychol."},{"key":"9037_CR27","unstructured":"Package \u201cpoLCA\u201d Type Package Title Polytomous Variable Latent Class Analysis. Published online 2022. https:\/\/github.com\/dlinzer\/poLCA. Accessed 13 April 2023."},{"key":"9037_CR28","doi-asserted-by":"publisher","unstructured":"Saito Y, Omae Y, Nagashima K, et al. Phenotyping of atrial fibrillation with cluster analysis and external validation. Heart. Published online June 2023: heartjnl-2023\u2013322447. https:\/\/doi.org\/10.1136\/heartjnl-2023-322447.","DOI":"10.1136\/heartjnl-2023-322447"},{"key":"9037_CR29","doi-asserted-by":"publisher","unstructured":"Bisson A, M Fawzy A, Romiti GF, et al. Phenotypes and outcomes in non-anticoagulated patients with atrial fibrillation: An unsupervised cluster analysis. Arch Cardiovasc Dis. 2023;116(6\u20137):342\u2013351. https:\/\/doi.org\/10.1016\/j.acvd.2023.06.001.","DOI":"10.1016\/j.acvd.2023.06.001"},{"key":"9037_CR30","doi-asserted-by":"publisher","unstructured":"Guo Y, Romiti GF, Proietti M, et al. Mobile health technology integrated care in older atrial fibrillation patients: a subgroup analysis of the mAFA-II randomised clinical trial. Age Ageing. 2022;51(11). https:\/\/doi.org\/10.1093\/ageing\/afac245.","DOI":"10.1093\/ageing\/afac245"},{"issue":"9","key":"9037_CR31","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/EUROPACE\/EUAB079","volume":"23","author":"H Ogawa","year":"2021","unstructured":"Ogawa H, An Y, Nishi H, et al. Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. Europace. 2021;23(9):1369-1379. https:\/\/doi.org\/10.1093\/EUROPACE\/EUAB079.","journal-title":"Europace."},{"key":"9037_CR32","doi-asserted-by":"publisher","unstructured":"Proietti M, Romiti GF, Corica B, et al. Features of Clinical Complexity in European Patients with Atrial Fibrillation: A Report from a European Observational Prospective AF Registry. Curr Probl Cardiol. Published online April 2023:101752. https:\/\/doi.org\/10.1016\/J.CPCARDIOL.2023.101752.","DOI":"10.1016\/J.CPCARDIOL.2023.101752"},{"key":"9037_CR33","doi-asserted-by":"publisher","unstructured":"Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev. 2022;79. https:\/\/doi.org\/10.1016\/J.ARR.2022.101652.","DOI":"10.1016\/J.ARR.2022.101652"},{"issue":"31","key":"9037_CR34","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1093\/EURHEARTJ\/EHAC265","volume":"43","author":"SP Johnsen","year":"2022","unstructured":"Johnsen SP, Proietti M, Maggioni AP, Lip GYH. A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur Heart J. 2022;43(31):2916-2918. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAC265.","journal-title":"Eur Heart J."},{"issue":"1","key":"9037_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/07853890.2020.1799241","volume":"53","author":"M Kozie\u0142","year":"2021","unstructured":"Kozie\u0142 M, Simovic S, Pavlovic N, et al. Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Ann Med. 2021;53(1):17-25. https:\/\/doi.org\/10.1080\/07853890.2020.1799241.","journal-title":"Ann Med."},{"issue":"11","key":"9037_CR36","doi-asserted-by":"publisher","first-page":"15089","DOI":"10.1161\/JAHA.119.015089","volume":"9","author":"N Chen","year":"2020","unstructured":"Chen N, Alam AB, Lutsey PL, et al. Polypharmacy, adverse outcomes, and treatment effectiveness in patients \u226575 with atrial fibrillation. J Am Heart Assoc. 2020;9(11):15089. https:\/\/doi.org\/10.1161\/JAHA.119.015089.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"9037_CR37","doi-asserted-by":"publisher","first-page":"e001257","DOI":"10.1136\/openhrt-2020-001257","volume":"7","author":"C Gallagher","year":"2020","unstructured":"Gallagher C, Nyfort-Hansen K, Rowett D, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020;7(1):e001257. https:\/\/doi.org\/10.1136\/openhrt-2020-001257.","journal-title":"Open Heart."},{"issue":"6","key":"9037_CR38","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/JCN.0000000000000401","volume":"32","author":"MI Cajita","year":"2017","unstructured":"Cajita MI, Hodgson NA, Budhathoki C, Han HR. Intention to Use mHealth in Older Adults With Heart Failure. J Cardiovasc Nurs. 2017;32(6):E1-E7. https:\/\/doi.org\/10.1097\/JCN.0000000000000401.","journal-title":"J Cardiovasc Nurs."},{"issue":"8","key":"9037_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/CIN.0000000000000442","volume":"36","author":"MI Cajita","year":"2018","unstructured":"Cajita MI, Hodgson NA, Lam KW, Yoo S, Han HR. Facilitators of and Barriers to mHealth Adoption in Older Adults with Heart Failure. CIN - Comput Inform Nurs. 2018;36(8):376-382. https:\/\/doi.org\/10.1097\/CIN.0000000000000442.","journal-title":"CIN - Comput Inform Nurs."},{"issue":"12","key":"9037_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/AGEING\/AFAC252","volume":"51","author":"LA Ritchie","year":"2022","unstructured":"Ritchie LA, Harrison SL, Penson PE, et al. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003\u20132018. Age Ageing. 2022;51(12):1-10. https:\/\/doi.org\/10.1093\/AGEING\/AFAC252.","journal-title":"Age Ageing."},{"issue":"11","key":"9037_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/S41569-021-00561-0","volume":"18","author":"UR Essien","year":"2021","unstructured":"Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18(11):763-773. https:\/\/doi.org\/10.1038\/S41569-021-00561-0.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"9037_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","volume":"18","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med. 2020;18(1):401. https:\/\/doi.org\/10.1186\/s12916-020-01870-w.","journal-title":"BMC Med."},{"issue":"1","key":"9037_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4310\/23-SII785","volume":"17","author":"T Fei","year":"2024","unstructured":"Fei T, Hanfelt JJ, Peng L. Latent Class Proportional Hazards Regression with Heterogeneous Survival Data. Stat Interface. 2024;17(1):79-90. https:\/\/doi.org\/10.4310\/23-SII785.","journal-title":"Stat Interface."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-09037-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:15:56Z","timestamp":1746101756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-09037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["9037"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-09037-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"The study was approved by the Central Medical Ethic Committee of Chinese PLA General Hospital and by local institutional review boards and was conducted in accordance with the Declaration of Helsinki and the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline; all the patients gave their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic Approval and Consent to Participate:"}},{"value":"GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. MP is investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement no. 899871. GYHL has been consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. GYHL is a NIHR Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871. All other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}}]}}